Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 1
1988 1
1989 1
1993 1
1994 1
1996 1
1997 4
1998 3
1999 1
2000 1
2001 1
2002 2
2004 2
2005 1
2010 1
2011 2
2012 2
2013 3
2015 1
2016 1
2017 2
2018 2
2019 3
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Siegal DM, et al. Among authors: leeds jm. N Engl J Med. 2015 Dec 17;373(25):2413-24. doi: 10.1056/NEJMoa1510991. Epub 2015 Nov 11. N Engl J Med. 2015. PMID: 26559317 Free article. Clinical Trial.
Pharmaceutical Development for Huntington’s Disease.
Morse RJ, Leeds JM, Macdonald D, Park L, Toledo-Sherman L, Pacifici R. Morse RJ, et al. Among authors: leeds jm. In: Lo DC, Hughes RE, editors. Neurobiology of Huntington's Disease: Applications to Drug Discovery. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 8. In: Lo DC, Hughes RE, editors. Neurobiology of Huntington's Disease: Applications to Drug Discovery. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 8. PMID: 21882420 Free Books & Documents. Review.
Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa.
Siegal D, Lu G, Leeds JM, Karbarz M, Castillo J, Mathur V, Hutchaleelaha A, Sinha U, Kitt M, McClure M, Hollenbach SJ, Curnutte JT, Conley PB, Crowther M. Siegal D, et al. Among authors: leeds jm. Blood Adv. 2017 Sep 22;1(21):1827-1838. doi: 10.1182/bloodadvances.2017007112. eCollection 2017 Sep 26. Blood Adv. 2017. PMID: 29296829 Free PMC article.
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
Coffey GP, Feng J, Betz A, Pandey A, Birrell M, Leeds JM, Der K, Kadri S, Lu P, Segal J, Wang YL, Michelson G, Curnutte JT, Conley PB. Coffey GP, et al. Among authors: leeds jm. Clin Cancer Res. 2019 Feb 15;25(4):1174-1184. doi: 10.1158/1078-0432.CCR-18-1047. Epub 2018 Oct 17. Clin Cancer Res. 2019. PMID: 30333224 Clinical Trial.
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
Hamlin PA, Flinn IW, Wagner-Johnston N, Burger JA, Coffey GP, Conley PB, Michelson G, Leeds JM, Der K, Kim Y, Sabalvaro-Torres A, Birrell M, Pandey A, Curnutte JT, Patel MR. Hamlin PA, et al. Among authors: leeds jm. Am J Hematol. 2019 Apr;94(4):E90-E93. doi: 10.1002/ajh.25387. Epub 2019 Jan 8. Am J Hematol. 2019. PMID: 30592080 Free article. Clinical Trial. No abstract available.
Development of ST-246® for Treatment of Poxvirus Infections.
Jordan R, Leeds JM, Tyavanagimatt S, Hruby DE. Jordan R, et al. Among authors: leeds jm. Viruses. 2010 Nov;2(11):2409-2435. doi: 10.3390/v2112409. Epub 2010 Nov 3. Viruses. 2010. PMID: 21994624 Free PMC article.
37 results